查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047959

臨床試驗配對軟體市場－全球產業規模、佔有率、趨勢、機會與預測：部署模式、最終用途、地區和競爭格局（2021-2031年）

Clinical Trials Matching Software Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Deployment Mode, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床試驗配對軟體市場預計將經歷顯著成長，從 2025 年的 1.9623 億美元成長到 2031 年的 3.2711 億美元，複合年成長率為 8.89%。

這種專業的數位化解決方案透過基於特定研究標準自動分析患者健康記錄，簡化了受試者識別流程，從而加快了受試者招募速度，並減輕了篩檢複雜方案所需的人工負擔。市場擴張的根本驅動力在於臨床試驗日益成長的複雜性。這是因為需要精準篩選患者以避免代價高昂的營運延誤，同時也需要最大限度地降低藥物研發成本，以及醫療保健數據的廣泛數位化。然而，該領域面臨著與資料互通性和嚴格的隱私法規相關的重大挑戰，這些挑戰阻礙了不同系統之間敏感資訊的無縫交換。統計數據顯示，到2025年，80%的臨床試驗將無法招募到足夠的患者，這凸顯了高效匹配工具對於確保試驗可行性的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1.9623億美元
市場規模：2031年 3.2711億美元
複合年成長率：2026-2031年 8.89%
成長最快的細分市場 製藥和生物技術公司
最大的市場 北美洲

市場促進因素

市場轉型的主要驅動力是人工智慧 (AI) 和機器學習的融合，以實現精準匹配，從而能夠自動分析非結構化數據，例如醫生觀察和影像數據。這項進步使申辦方能夠以前所未有的準確度識別合格的受試者，直接消除人工篩檢的低效性，而人工篩選往往會導致招募失敗。產業策略投資重點也反映了這一轉變，63% 的生命科學專業人士將人工智慧列為未來幾年的關鍵技術投資領域。同時，臨床試驗方案日益複雜化也進一步推動了市場發展，需要先進的數位化解決方案來管理複雜的合格標準並減輕營運負擔。隨著研究中終點指標和數據要求的不斷提高，傳統的受試者招募方法已無法滿足需求，因此依賴先進的軟體至關重要。這一趨勢也得到了以下事實的支持：到 2024 年，96% 的臨床試驗都至少包含一項基於風險的品管要素。採用這些配對技術的財務基礎十分穩固，全球生物製藥研發資金在 2024 年達到 1,020 億美元，是過去十年來的最高水準。

市場挑戰

資料互通性和嚴格的隱私法規是全球臨床試驗配對軟體市場成長的主要障礙。該軟體的核心功能依賴於其聚合和分析來自各種電子健康記錄 (EHR) 和醫院系統的大量資料集的能力。然而，目前的醫療保健格局因資料孤島和不相容的格式而支離破碎，使得無縫提取患者資訊在技術上極具挑戰性，且成本高昂。這種整合失敗直接削弱了該技術的核心提案，因為匹配工具無法立即存取或解讀患者病歷，導致自動化合格流程失效。此外，不斷發展的隱私框架的嚴格要求迫使供應商實施複雜的合規協議，從而顯著延長了部署週期。這些技術障礙阻礙了醫療機構採用新的數位工具。美國醫學會 (AMA) 2024 年的一份報告指出，84% 的醫生要求無縫整合 EHR，87% 的醫生要求資料隱私保障，並將此視為採用新的數位醫療技術的關鍵前提條件。技術相容性和安全性方面的這些高門檻限制了市場擴張，因為醫療機構不願購買無法保證與現有基礎設施即時合規整合的解決方案。

市場趨勢

隨著去中心化和混合型臨床試驗生態系統的擴展，市場格局正在顯著重塑。這使得受試者的識別從傳統的實體試驗點轉向更廣泛、地域分散的患者群體。這一趨勢需要能夠與遠端資料擷取工具（例如電子知情同意平台和穿戴式裝置）整合的配對軟體。這將使申辦方能夠篩檢和招募那些無法前往傳統大學醫院的個人。透過消除地理障礙，這些數位生態系統將擴大受試者招募派餅，並顯著改善臨床試驗的可近性，尤其是在偏遠地區。塔夫茨中心2025年1月的一項分析支持了這一模式的有效性，該分析發現，去中心化臨床試驗提高了整體性，並將亞裔受試者的比例從傳統基於試驗點的研究中的14.2%提高到20.9%。同時，在FDA的《聯邦藥物濫用和再授權法案》（FDORA）多元化行動計劃等新監管要求的背景下，實施以多元化為重點的招募演算法已成為一項至關重要的優先事項。與標準合格匹配不同，這些專門的演算法優先考慮人口統計平衡，透過專門針對患者資料庫中代表性不足的種族和民族亞群體，確保符合聯邦指南。這種方法不僅符合法律標準，而且透過反映多樣化的基因譜，提高了研究數據的科學有效性。 2025年1月，WCG Clinical報告稱，在採用綜合設計策略的臨床試驗中，不同患者群體的保留率提高了30%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球臨床試驗配對軟體市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 部署方式（Web/雲端、本機部署）
    • 按最終用途（製藥和生物技術公司、合約研究組織、醫療設備製造商）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美臨床試驗配對軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲臨床試驗配對軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區臨床試驗配對軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲臨床試驗匹配軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美臨床試驗配對軟體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球臨床試驗配對軟體市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • IBM Watson Health
  • Antidote Technologies
  • Deep 6 AI
  • TriNetX
  • Clinerion
  • ConcertAI
  • Trialspark
  • Clario
  • Advarra
  • ArisGlobal

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16722

The Global Clinical Trials Matching Software Market is poised for substantial growth, projected to increase from USD 196.23 Million in 2025 to USD 327.11 Million by 2031, at an 8.89% CAGR. This specialized digital solution streamlines participant identification by automatically analyzing patient health records against specific study criteria, thereby accelerating recruitment and reducing the manual effort involved in screening complex protocols. The market's expansion is fundamentally driven by the escalating complexity of clinical studies, which necessitates precise patient targeting to avoid costly operational delays, alongside the imperative to minimize drug development costs and the pervasive digitization of healthcare data. However, the sector faces significant hurdles regarding data interoperability and stringent privacy regulations that impede the seamless exchange of sensitive information across disparate systems. This challenge is highlighted by the statistic that in 2025, 80% of clinical trials failed to recruit enough patients, underscoring the critical need for efficient matching tools to ensure trial viability.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 196.23 Million
Market Size 2031USD 327.11 Million
CAGR 2026-20318.89%
Fastest Growing SegmentPharmaceutical & Biotechnology Companies
Largest MarketNorth America

Market Driver

A key transformative driver for the market is the integration of Artificial Intelligence and Machine Learning for precision matching, enabling the automated analysis of unstructured datasets such as physician notes and imaging. This advancement empowers sponsors to identify eligible participants with unprecedented accuracy, directly addressing the inefficiencies of manual screening that often lead to recruitment failures. The industry's strategic investment priorities reflect this shift, with 63% of life science professionals citing AI as their primary technology investment area for the coming years. Concurrently, the increasing complexity of clinical trial protocols further propels the market, demanding advanced digital solutions to manage intricate eligibility criteria and alleviate operational burdens. As studies incorporate more endpoints and rigorous data requirements, traditional recruitment methods prove inadequate, making reliance on sophisticated software essential. This trend is reinforced by the fact that 96% of clinical trials in 2024 incorporated at least one risk-based quality management component. The financial foundation for adopting these matching technologies is robust, with global biopharmaceutical R&D funding reaching a ten-year high of $102 billion in 2024.

Market Challenge

Data interoperability and strict privacy regulations present a formidable impediment to the growth of the Global Clinical Trials Matching Software Market. The core functionality of this software hinges on its capacity to aggregate and analyze extensive datasets from various Electronic Health Records (EHRs) and hospital systems. Yet, the current healthcare landscape is fragmented by data silos with incompatible formats, rendering the seamless extraction of patient information technically challenging and financially burdensome. When matching tools are unable to instantly access or interpret patient histories due to these integration failures, the automated eligibility determination process becomes ineffective, directly undermining the technology's primary value proposition. Moreover, the stringent requirements of evolving privacy frameworks compel vendors to implement complex compliance protocols, significantly extending implementation timelines. This technical friction discourages healthcare providers from adopting new digital tools, as evidenced by a 2024 American Medical Association report stating that 84% of physicians require seamless EHR integration and 87% demand data privacy assurances as critical prerequisites for adopting new digital health technologies. This high threshold for technical compatibility and security limits the market's reach, as institutions delay purchasing solutions that cannot guarantee immediate, compliant integration with their existing infrastructure.

Market Trends

The market is being significantly reshaped by the expansion into decentralized and hybrid clinical trial ecosystems, which shifts participant identification from traditional physical sites to broader, geographically dispersed patient populations. This trend necessitates matching software capable of integrating with remote data capture tools, such as eConsent platforms and wearable devices, enabling sponsors to screen and enroll individuals who cannot attend traditional academic medical centers. By eliminating geographical barriers, these digital ecosystems expand the recruitment funnel and notably enhance trial accessibility, particularly for remote communities. The efficacy of this model is supported by a January 2025 Tufts Center analysis, showing decentralized clinical trials improved inclusivity, raising Asian participant representation to 20.9% compared to 14.2% in conventional site-based studies. Simultaneously, the implementation of diversity-focused recruitment algorithms has become a critical priority, driven by new regulatory mandates like the FDA's FDORA requirements for diversity action plans. Unlike standard eligibility matching, these specialized algorithms prioritize demographic balance by specifically targeting underrepresented racial and ethnic subgroups within patient databases to ensure compliance with federal guidelines. This focus not only meets legal standards but also strengthens the scientific validity of study data by reflecting diverse genetic profiles, with WCG Clinical reporting in January 2025 that trials incorporating inclusive design strategies achieved a 30% higher retention rate among diverse patient populations.

Key Market Players

  • IBM Watson Health
  • Antidote Technologies
  • Deep 6 AI
  • TriNetX
  • Clinerion
  • ConcertAI
  • Trialspark
  • Clario
  • Advarra
  • ArisGlobal

Report Scope

In this report, the Global Clinical Trials Matching Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Matching Software Market, By Deployment Mode

  • Web & Cloud-based
  • On-premises

Clinical Trials Matching Software Market, By End-use

  • Pharmaceutical & Biotechnology Companies
  • CROs
  • Medical Device Firms

Clinical Trials Matching Software Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trials Matching Software Market.

Available Customizations:

Global Clinical Trials Matching Software Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trials Matching Software Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Deployment Mode (Web & Cloud-based, On-premises)
    • 5.2.2. By End-use (Pharmaceutical & Biotechnology Companies, CROs, Medical Device Firms)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Clinical Trials Matching Software Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Deployment Mode
    • 6.2.2. By End-use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clinical Trials Matching Software Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Deployment Mode
        • 6.3.1.2.2. By End-use
    • 6.3.2. Canada Clinical Trials Matching Software Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Deployment Mode
        • 6.3.2.2.2. By End-use
    • 6.3.3. Mexico Clinical Trials Matching Software Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Deployment Mode
        • 6.3.3.2.2. By End-use

7. Europe Clinical Trials Matching Software Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Deployment Mode
    • 7.2.2. By End-use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clinical Trials Matching Software Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Deployment Mode
        • 7.3.1.2.2. By End-use
    • 7.3.2. France Clinical Trials Matching Software Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Deployment Mode
        • 7.3.2.2.2. By End-use
    • 7.3.3. United Kingdom Clinical Trials Matching Software Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Deployment Mode
        • 7.3.3.2.2. By End-use
    • 7.3.4. Italy Clinical Trials Matching Software Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Deployment Mode
        • 7.3.4.2.2. By End-use
    • 7.3.5. Spain Clinical Trials Matching Software Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Deployment Mode
        • 7.3.5.2.2. By End-use

8. Asia Pacific Clinical Trials Matching Software Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Deployment Mode
    • 8.2.2. By End-use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clinical Trials Matching Software Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Deployment Mode
        • 8.3.1.2.2. By End-use
    • 8.3.2. India Clinical Trials Matching Software Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Deployment Mode
        • 8.3.2.2.2. By End-use
    • 8.3.3. Japan Clinical Trials Matching Software Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Deployment Mode
        • 8.3.3.2.2. By End-use
    • 8.3.4. South Korea Clinical Trials Matching Software Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Deployment Mode
        • 8.3.4.2.2. By End-use
    • 8.3.5. Australia Clinical Trials Matching Software Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Deployment Mode
        • 8.3.5.2.2. By End-use

9. Middle East & Africa Clinical Trials Matching Software Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Deployment Mode
    • 9.2.2. By End-use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Clinical Trials Matching Software Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Deployment Mode
        • 9.3.1.2.2. By End-use
    • 9.3.2. UAE Clinical Trials Matching Software Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Deployment Mode
        • 9.3.2.2.2. By End-use
    • 9.3.3. South Africa Clinical Trials Matching Software Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Deployment Mode
        • 9.3.3.2.2. By End-use

10. South America Clinical Trials Matching Software Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Deployment Mode
    • 10.2.2. By End-use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Clinical Trials Matching Software Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Deployment Mode
        • 10.3.1.2.2. By End-use
    • 10.3.2. Colombia Clinical Trials Matching Software Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Deployment Mode
        • 10.3.2.2.2. By End-use
    • 10.3.3. Argentina Clinical Trials Matching Software Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Deployment Mode
        • 10.3.3.2.2. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clinical Trials Matching Software Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IBM Watson Health
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Antidote Technologies
  • 15.3. Deep 6 AI
  • 15.4. TriNetX
  • 15.5. Clinerion
  • 15.6. ConcertAI
  • 15.7. Trialspark
  • 15.8. Clario
  • 15.9. Advarra
  • 15.10. ArisGlobal

16. Strategic Recommendations

17. About Us & Disclaimer